{'fraction_non_alphanumeric': 0.0121580547112462, 'fraction_numerical': 0.00303951367781155, 'mean_word_length': 5.415584415584416, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Combination therapy with imatinib mesylate (sti571): synopsis of in vitro studies

Chronic myelogenous leukaemia (CML) is the first malignancy in which knowledge about the pathomechanisms of the disease has led to the development of a specific and highly effective molecular therapy. The first clinical trials with the tyrosine kinase inhibitor imatinib mesylate showed high response rates with minimal toxicity and raised hope for a possible cure of CML by drug therapy alone. However, not all patients show a complete response and even in responders relapses continue to occur, particularly in advanced phases of the disease. Combination therapy with imatinib and established or investigational antileukaemic agents may lead to an increase in the response rates and remission duration. This review summarizes relevant in vitro studies in the hope that translation of promising preclinical data into clinical trials will lead to further increases in the life expectancy of CML patients.